Original ArticleInternational Comparison of Poststroke Resource Use: A Longitudinal Analysis in Europe
Introduction
The value of stroke prevention and treatment strategies depends not only on the nature of the acute event and the effectiveness of the intervention but also on the type and volume of resources used. Such economic evaluations typically take the form of cost-effectiveness analyses, a foundation for clinical and policy decision making. Costs relevant to economic evaluations include short-term costs (eg, acute hospitalization) and long-term costs (eg, rehabilitation, nursing home, and home-based services).1 The economic case for interventions that reduce stroke severity is based on the extent to which the therapies reduce institutional and home-based long-term care costs. If not cost saving, even treatments that are modestly effective in reducing stroke severity can be cost effective.2
Although long-term costs often represent a large proportion of the total costs induced by stroke,3 data on long-term poststroke resource use are sparse, especially regarding the trajectory of costs by severity. Longitudinal studies, which are ideal for assessing long-term stroke costs, can be difficult and expensive.4 Moreover, resource use is highly variable, often reflecting idiosyncratic regional patterns based on clinical training, resource availability, and reimbursement.1, 5, 6 Because policy decisions are often local, resource-use studies should capture this diversity by addressing issues of regional variations.7
This article aims to quantify the estimated poststroke utilization of inpatient and home-based services as a function of disability and European regions, using the first 2 waves' data of Survey of Health, Ageing and Retirement in Europe (SHARE)8 and to contribute to the current understanding of long-term resource utilization for stroke by projecting and comparing the resource-use patterns in Europe.
Section snippets
Data Source and Study Population
Our study population was chosen from the respondents of the first 2 waves (wave 1 in 2004/2005 and wave 2 in 2006/2007) of the SHARE, which is a cross-national longitudinal survey of individuals dwelling in the community aged at least 50 years on their health, socioeconomic status, and social and family networks (n = 62,127). SHARE is notably consistent with the US Health and Retirement Study and the English Longitudinal Study of Ageing.8
We selected respondents who answered affirmatively to the
Results
Sixty percent of our study sample resided in Central Europe, and the rest of the population was balanced between Northern (21%) and Southern Europe (19%; Table 1). The average duration since stroke was 25.9 months; it was similar across all the regions (P value = .983); 30.2% of our study population had moderate ADL limitations; 6.6% had severe ADL limitations. About 6% of the study population had more than 1 stroke at the interview date, which was relatively homogenous across all regions (P
Discussion
In this study, we primarily found that poststroke resource use across all European regions was positively and strongly associated with the level of ADL limitations with patients' demographic information and the type of acute and/or subacute treatment received; several studies in the countries participating in SHARE have highlighted the effect of functional disability on poststroke resource utilization. A cohort study of stroke patients in the Netherlands found that one of the most important
Acknowledgments
This article uses data from SHARE waves 1 and 2, release 2.6.0, as of November 29 2013 (DOI: 10.6103/SHARE.w1.260 and 10.6103/SHARE.w2.260). The SHARE data collection has been primarily funded by the European Commission through the fifth Framework Programme (project QLK6-CT-2001-00360 in the thematic programme Quality of Life), through the sixth Framework Programme (projects SHARE-I3, RII-CT-2006-062193, COMPARE, CIT5-CT-2005-028857, and SHARELIFE, CIT4-CT-2006-028812), and through the seventh
References (25)
- et al.
Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty
Value Health
(2005) - et al.
Regional variation in health care utilization and outcomes in ischemic stroke
J Stroke Cerebrovasc Dis
(2003) - et al.
Strategies for incorporating resource allocation and economic considerations: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest
(2008) - et al.
Health care resource use and stroke outcome—multinational comparisons within the GAIN International trial
Int J Technol Assess Health Care
(2003) - et al.
A population-based study of hospital care costs during 5 years after transient ischemic attack and stroke
Stroke
(2012) - et al.
Cost of stroke in Europe
Eur J Neurol
(2005) - et al.
Hospital services for stroke care. A European Perspective. European Study of Stroke Care
Stroke
(1996) - et al.
Data resource profile: the Survey of Health, Ageing and Retirement in Europe (SHARE)
Int J Epidemiol
(2013) - et al.
Predicting the cost of illness: a comparison of alternative models applied to stroke
Med Decis Making
(1998) - et al.
Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function
JAMA
(1963)
Cerebral vascular accidents in patients over the age of 60. II. Prognosis
Scott Med J
Informal and formal care among single-living elderly in Europe
Health Econ
Cited by (0)
This work was funded by the Singapore Ministry of Health's National Medical Research Council under its Singapore Translational Research (STaR) Award grant (grant number NMRC|STaR|0005|2009) as part of the project “Establishing a Practical and Theoretical Foundation for Comprehensive and Integrated Community, Policy and Academic Efforts to Improve Dementia Care in Singapore.” This study is also funded by the US National Institute on Aging (U01 AG09740-13S2, P01 AG005842, P01 AG08291, P30 AG12815, R21 AG025169, Y1-AG-4553-01, IAG BSR06-11, and OGHA 04-064), the German Ministry of Education and Research, and various national sources.
Disclosures: D.B.M. has worked as a consultant (<$10,000) to Boehringer Ingelheim. The other authors have no conflicts to report.